Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shinobi Therapeutics

Request full access

Developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs

South San Francisco, United StatesFounded 2023Biotech & Life Sciences

About Shinobi Therapeutics

Shinobi Therapeutics is a pioneering biotech company specializing in immune-evasive induced pluripotent stem cell (iPSC) therapies. The company focuses on developing innovative treatments for solid tumor cancers by generating T cells from iPSCs that can evade the immune system. This approach aims to make cell therapies more accessible, reduce costs, and shorten treatment timelines, ultimately benefiting millions of patients.

Operating in the biotechnology and healthcare markets, Shinobi Therapeutics serves a diverse range of clients, including top-tier research institutions, healthcare providers, and investors. The business model revolves around partnering with leading institutions to source and advance groundbreaking research in immune-evasive iPSC-derived cell therapies. Revenue is generated through research partnerships, grants, and potential commercialization of their therapies.

Shinobi Therapeutics' technology has been validated in numerous scientific publications and is led by a team of industry leaders with roots in Kyoto and San Francisco. The company's comprehensive immune evasion technology shields against T cells, innate immunity, and antibody-mediated rejection, making their therapies highly effective.

Source: Dealroom company data

At a glance

Status
Operational
Employees
40
Open positions
None listed
Dealroom signal
81.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
GRANTOther financing Aug 2024 $59M — AMED ↗
SERIES AOther financing Aug 2024 $9M $255M Mitsubishi UFJ Capital · Yosemite ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Shinobi Therapeutics website traffic

Latest recorded traffic for Shinobi Therapeutics is 2.1K monthly website visits, up 255.9% over the last three months. Shinobi Therapeutics's team declined 2.4% over the past year.

Latest monthly visits2.1K 3-month web change+255.9% 1-year team growth-2.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shinobi Therapeutics in the South San Francisco ecosystem

Live from Dealroom

The Shinobi Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

Series A6 investors entered at this stage

  • EQT Life Sciences
  • Fast Track Initiative
  • Astellas Venture
  • JIC Venture Growth Investments
  • Mitsubishi UFJ Capital
  • Yosemite

Other known investors2 additional known investors

  • Kyoto University
  • University of California, San Francisco
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 8 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States78.6%
🇯🇵 Japan21.4%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shinobi Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shinobi Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.